Thromboembolic risk in patients with lung cancer receiving systemic therapy

In this retrospective study, we investigated the influence of chemotherapy and immunotherapy on thromboembolic risk among United States Veterans with lung cancer during their first 6 months (180 days) following initiation of systemic therapy. Included patients received treatment with common front-line agents that were divided into four groups: chemotherapy alone, immunotherapy alone, combination of chemo- and immunotherapies, and molecularly targeted therapies (control group). The cohort experienced a 7 center dot 4% overall incidence of thrombosis, but the analysis demonstrated significantly different rates among the different groups. We explored models incorporating multiple confounding variables as well as the competing risk of death, and these results indicated that both chemo- and immunotherapies were associated with an increased incidence of thrombosis, either alone or combined, compared with the control group (7 center dot 56%, P = 2.2 x 10(-16); 10 center dot 2%, P = 2.2 x 10(-16); and 7 center dot 87%, P = 2.4 x 10(-14) respectively vs. 4 center dot 10%). The Khorana score was found to be associated with increased risk, as were vascular disease and metastases. We found an association between risk of thrombosis and the use of anticoagulation, accounting for several confounders, including history of thrombosis. Further study is warranted to better determine the drivers of thromboembolic risk and to identify ways to mitigate this risk for patients.

Automated summary

The study revealed that both chemotherapy and immunotherapy were associated with an increased risk of thrombosis in US Veterans with lung cancer. Factors such as the Khorana score, vascular disease, and metastases were also found to be related to higher risk of thrombosis. Further research is needed to identify ways to reduce this risk for patients.